Publication | Open Access

Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies

OncologyMedicineImmunologyAdvanced Solid TumorsImmune Checkpoint InhibitorAnti-cancer AgentRetinoic Acid-inducible GeneCancer TreatmentPharmacologyPhase 1